Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of BL-M02D1 in advanced or metastatic non-small cell lung cancer and other solid tumors
CTR20232085Phase 2Active
- Sponsor
- Biokin Pharmaceutical
- Start
- Oct 2023
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of BL-M02D1 in non-small cell lung cancer (NSCLC) and Nonhematologic neoplasms, sponsored by Biokin Pharmaceutical. Primary endpoints: Recommended phase II dose and Objective response rate. Started Oct 2023; status: active.
02
Drugs
BL-M02D1
03
Conditions
non-small cell lung cancer (NSCLC)Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20232085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232085.